Business Wire

CHEN-CHIEN-JEN

Share
3 Factors Contribute to Taiwan’s Success Against COVID-19: Former VP

Ever wondered how Taiwan, despite its geographical proximity to China, managed to keep the COVID-19 at bay? Well, Taiwan’s former vice president, Chen Chien-jen, has some answers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005239/en/

“I think there were three important factors that contributed to this: a prudent attitude in dealing with COVID-19, prompt actions in responding to different situations, and forward planning before a crisis,” Chen said in a webcast program produced by the Talent Circulation Alliance and the American Institute in Taiwan June 24.

One example of these was Taiwan’s learning of the situation in Wuhan, where the coronavirus was first detected in late 2019, from a bulletin board system in Taiwan and immediately screening passengers arriving from that city, Chen said.

Chen, an epidemiologist, said Taiwan also began taking measures to prevent hospital infections, enhanced contact tracing, and quarantined people who had close contact with confirmed cases.

In addition, the activation of the Central Epidemic Command Center to coordinate government response, the requisition of face masks, and the pre-positioning of medical supplies all contributed to Taiwan’s success against COVID-19, Chen said.

Taiwan was able to increase its daily production capacity of surgical masks from 1.88 million to 20 million in just over a month.

The government’s detailed explanation of its coronavirus prevention measures gave the public confidence in its ability to handle the situation, resulting in people abiding by government instructions, including washing hands frequently, wearing face masks, and following home quarantine rules, he said.

Chen, who served as Taiwan's health minister during the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003, also stressed the importance of talent circulation in epidemic prevention cooperation.

“No country can combat any emerging communicable disease alone,” Chen said.

During SARS, for example, Chen said Taiwan did not receive help from the WHO because of its ongoing exclusion from the U.N. special agency. Fortunately, with the assistance of 20 specialists sent by the U.S. Centers for Disease Control and Prevention, Taiwan was able to weather the health crisis, he said.

Meanwhile, the U.S. specialists brought back what they had learned from Taiwan and contributed to the setting of standard procedures in America in dealing with SARS, Chen said, “The world can be a better place if people cooperate with each other, circulate talent, and share technologies.”

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release

This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where

Smartstream Introduces Agentic AI ‘Smart Agents’ for Investigations and Exceptions Handling4.12.2025 09:55:00 CET | Press release

Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the preview of Smart Agents for Investigations, a breakthrough in financial operations that brings augmented and autonomous exception handling to reconciliations and back-office processes. The new investigation agent combines domain-trained AI agents, workflow adoption, and embedded controls to triage, investigate, resolve, and learn from exceptions - reducing manual effort, accelerating time to resolution, and strengthening auditability. It will add a layer of intelligence on top of Smartstream’s current reconciliations and exceptions solutions. It understands the breaks context, adheres to customer playbooks and reaches out for missing information. It documents every step for audit and compliance, allowing analysts to focus on risk. Finally, it augments the analyst’s investigation with contextual information radically changing the user experience to review and a

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes4.12.2025 09:00:00 CET | Press release

The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA™ platform to optimise NANOBODY® molecules for multiple new targets in the area of inflammation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204759388/en/ “We are truly excited abo

GoWit One: The Unified AI Operating System Set to Revolutionize Commerce & Retail Media4.12.2025 07:09:00 CET | Press release

WPP Turkey has been selected as a pilot partner to deploy GoWit One, cutting campaign setup time to 10 minutes. GoWit, a global AdTech leader in omnichannel Commerce and Retail Media, announced the launch of GoWit One, the unified AI operating system that brings automation, unification, and real-time intelligence into a single ad platform for agencies operating across multiple retailers, channels, and markets. By bringing these three elements into one dashboard, GoWit One addresses the industry's most critical bottleneck: operational inefficiency. The platform enables agencies to manage campaigns across multiple retailers, channels, and markets, reducing manual AdOps workflows by 98%, turning a process that used to take hours into as little as 10 minutes. Solving the “Fragmentation Crisis” Despite the explosive growth of Retail Media, the industry faces a significant hurdle. According to the IAB, 70% of the market still lacks end-to-end AI adoption. Media buyers are currently forced to

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings4.12.2025 07:00:00 CET | Press release

‘BBB’ long-term issuer credit rating from S&P Global RatingsPositive outlook, reflecting expected profitability improvement, ramp up of Nemluvio, and continued deleveraging and balance sheet improvementRecognition of Galderma’s science-based dermatology portfolio and global operations Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation. S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye